Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

268

datasets available to search

ShareScore release 0.7.1

Reset

Dataset results

268 results for “IL-6”

Learn how ShareScore rates datasets ↗
zenodo40/100

Figure 3. Serum IL-6 in Physical characterization and wound healing properties of Zamzam water

Figure 3. Serum IL-6 level of treatment groups. ***Extremely high significant at p <0.001; **Extremely significant at p <0.01 on comparing with Group 2; ns: nonsignificant when compared to Group 3. Group 1: Normal control; Group 2: Disease control (wound without treatment); Group 3: Standard control (treatment with povidone iodine cream); Group 4: Zamzam water treatment group.

opencc-by-4.0Dec 2022View details →
zenodo40/100

Figure 2. Serum IL-6 in Wound-healing and cytokine-modulating potential of medicinal oil formulation comprising leaf extract of Murraya koenigii and olive oil

Figure 2. Serum IL-6 level of treatment groups. *The level of IL-6 enhanced 154% when compared to Group 1; #The level of IL-6 declined 38.86% when compared to Group 2; $The level of IL-1β declined 48.3% when compared to Group 2.

opencc-by-4.0Dec 2022View details →
zenodo40/100

Fig. 8. The IL-6 in Fig. 4 in Identification of Sexually Dimorphic Genes in Pectoral Fin as Molecular Markers for Assessing the Sex of Japanese Silver Eels ().

Fig. 8. The IL-6 expression levels of Japanese eel and giant mottled eel reared in different spectra. W: white light; B: blue light; G: green light; R: red light; black: dark. Different letters indicate significant differences between different spectra groups of the same eel species (p <0.05).

opencc-by-4.0Jun 2023View details →
zenodo40/100

IL-6 and TNF-α salivary levels according to the periodontal status in pregnant Portuguese women

<p>The aim of this study was to evaluate the expression levels of interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-&alpha;) in pregnant women with different periodontal status at Garcia de Orta Hospital (Almada, Portugal).</p>

opencc-by-4.0Feb 2018View details →
ClinicalTrials.gov40/100

A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection

ClinicalTrials.gov study NCT04343989. IPD Sharing: YES. Countries: 1. Publications: 1.

controlledIPD-YESFeb 2026View details →
zenodo36/100

The Regulation of Microglia Activity and the Production of IL-1α and IL-6 in the Degenerated Retina by Mesenchymal Stem Cells

<p><span>Activation of immune response and production of proinflammatory factors plays an important role in the development and progression of retinal degenerative diseases (RDD). For this reason, focusing on immunomodulation is potential option for the efficient ophthalmological therapy. Mesenchymal stem cells (MSCs) have been study in the treatment of RDD mainly due to their regenerative and neuroprotective actions. Nevertheless, MSCs also possess several immunomodulatory properties. Our study shows that NaIO<sub>3</sub>-induced degeneration increased <em>in vitro</em> and <em>in vivo</em> expression of genes for Interleukin (IL)-1&alpha; and IL-6 in the mouse retinal tissue. In addition, intraperitoneal application of NaIO<sub>3</sub> increased expression of gene for Iba-1 and infiltration of CD45<sup>+</sup>CD11b<sup>+</sup> cells into the retina. CD45<sup>+</sup> population was also responsible for the production of IL-1&alpha; while IL-6 was produced by CD45<sup>-</sup> cells. Cocultivation of degenerated retina in the presence of MSCs decreased the expression and production of both studied cytokines and expression of gene for Iba-1 in the retinal tissue. On contrary, it was observed that MSCs treated with supernatant from degenerated retina increased the expression of genes for cyclooxygenase-2, transforming growth factor-&beta;, programmed-death ligand 1 and nerve growth factor. These results show that MSCs are able to regulate immune reaction in the degenerated retinal environment.</span></p>

opencc-by-4.0Oct 2024View details →
dryad36/100

Interleukin-6 (IL-6) activates the NOTCH1 signaling pathway through E-proteins in endometriotic lesions

<p><b>Context:</b> NOTCH signaling is activated in endometriotic lesions but the exact mechanisms remains unclear. Interleukin-6 (IL-6), which is increased in the peritoneal fluid of women with endometriosis, induces NOTCH1 through E-proteins including E2A and HEB in cancer development.</p> <p><b>Objective:</b> To study the role of E-proteins in inducing NOTCH1 expression under the regulation of IL-6 in endometriosis.</p> <p><b>Setting and Design:</b> The expression of E2A, HEB and NOTCH1 was first investigated in endometrium of women with endometriosis and the baboon model of endometriosis. Regulation of E-proteins and NOTCH1 expression was examined after IL-6 stimulation and siRNA mediated inhibition of E2A or/and HEB in human endometriotic epithelial cells (12Z) <i>in vitro</i>, and subsequent following <i>in vivo </i>IL-6 treatment in the mouse model of endometriosis <i>in vivo</i>.</p> <p><b>Results: </b>E2A, HEB and NOTCH1 were significantly upregulated in glandular epithelium (GE) of ectopic endometrium compared to eutopic endometrium in both women and baboon model. IL-6 treatment upregulated the expression of NOTCH1 together with E2A and HEB in 12Z cells. siRNA inhibition of E2A and HEB or HEB alone decreased NOTCH1 expression. Binding efficiency of both E2A and HEB was significantly higher at the binding sites on the human NOTCH1 promoter after IL-6 treatment. Finally, IL-6 treatment resulted in a significantly increased number of endometriotic lesions along with the increased expression of E2A, HEB and NOTCH1 in GE of the lesions compared with the vehicle treated group in an endometriosis mouse model.</p> <p><span><b>Conclusions:</b> IL-6 induced NOTCH1 expression is mediated by E-proteins in the ectopic GE cells, which may promote endometriotic lesion development. </span></p>

opencc-zeroMar 2020View details →
zenodo36/100

An intron SNP rs2069837 in IL-6 is associated with osteonecrosis of the femoral head development

<p>Two variants (rs2069837, and rs13306435) in the IL-6 gene were identified and genotyped from 566 patients with ONFH and 566 healthy controls. The associations between IL-6 polymorphisms and ONFH susceptibility were assessed using odds ratio (OR) and 95% confidence interval (95% CI) via logistic regression. The results of the overall analysis revealed that IL-6 rs2069837 is correlated with decreased risk of ONFH among the Chinese Han population (<em>p</em> &lt; 0.05). In stratified analysis, rs2069837 also reduced the susceptibility to ONFH in older people (&gt; 51 years), males, nonsmokers, and nondrinkers (<em>p</em> &lt; 0.05).</p>

opencc-by-4.0Sep 2021View details →
zenodo36/100

Development of a Predictive Model for In-Hospital Mortality in COVID-19 Patients Using CAR, IL-6, IL-6/LY, and NLR: A Single-Center Study in Indonesia

<p>Figure 1. ROC Curve of CAR, IL-6, IL-6/LY, and NLR</p> <p>&nbsp;</p> <p>Figure 2. Kaplan Meier curve of (a) CAR (b) IL-6 (c) IL-6/LY (d) NLR blue line represents group above cut off and green one represents group below cut-off</p> <p>&nbsp;</p>

opencc-by-4.0May 2023View details →
ClinicalTrials.gov36/100

Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition

ClinicalTrials.gov study NCT03926117. IPD Sharing: YES. Countries: 1. Publications: 4.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

IL-6 in Exercise-Induced Anorexia

ClinicalTrials.gov study NCT03295968. IPD Sharing: NO. Countries: 1. Publications: 6.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

Effect Of Ophiochepalus Striatus Extract On Serum IGF-1 And IL-6 Levels In Elderly Patients With Sarcopenia

ClinicalTrials.gov study NCT05869383. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov36/100

AIDS 347: IL-6 Blockade in Treated HIV Infection

ClinicalTrials.gov study NCT02049437. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov36/100

Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition in Japan.

ClinicalTrials.gov study NCT04626505. IPD Sharing: YES. Countries: 1. Publications: 1.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov36/100

Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma)

ClinicalTrials.gov study NCT05463133. IPD Sharing: YES. Countries: 1. Publications: 3.

controlledIPD-YESFeb 2026View details →
dryad36/100

Interleukin-6 (IL-6) activates the NOTCH1 signaling pathway through E-proteins in endometriotic lesions

Open the record for dataset details and reuse information.

publicMar 2020View details →
zenodo32/100

Supplementary PyMOL sessions for "Small protein blockers of human IL-6 receptor alpha inhibit proliferation and migration of cancer cells"

<p>PyMOL sessions with summary of NEF variants docking to IL-6R. Supplementary to "Small protein blockers of human IL-6 receptor alpha inhibit proliferation and migration of cancer cells".</p>

opencc-by-4.0Nov 2023View details →
zenodo32/100

The ELISA results of serum, skin, and muscle TNF-α, IL-6, IL-1β, iNOS, and β-EP levels and HE staining results of skin and muscle in control group, model group, GSMO group, IMO group, and GSTO group.

Open the record for dataset details and reuse information.

opencc-by-4.0Mar 2024View details →
zenodo32/100

Supplemental Material - An IL-6 promoter variant (-174 G/C) augments IL-6 production and alters skeletal muscle transcription in response to exercise in mice.

<p>Supplemental Material for article: "An IL-6 promoter variant (-174 G/C) augments IL-6 production and alters skeletal muscle transcription in response to exercise in mice."</p>

opencc-by-4.0Nov 2024View details →
dryad32/100

Maternal and perinatal obesity induce bronchial obstruction and pulmonary hypertension via IL-6-FoxO1-axis in later life

<p>Obesity is a pre-disposing condition for chronic obstructive pulmonary disease, asthma, and pulmonary arterial hypertension. Accumulating evidence suggests that metabolic influences during development can determine chronic lung diseases (CLD). We demonstrate that maternal obesity causes early metabolic disorder in the offspring. Here, interleukin-6 induced bronchial and microvascular smooth muscle cell (SMC) hyperproliferation and increased airway and pulmonary vascular resistance. The key anti-proliferative transcription factor FoxO1 was inactivated via nuclear exclusion. These findings were confirmed using primary SMC treated with interleukin-6 and pharmacological FoxO1 inhibition as well as genetic FoxO1 ablation and constitutive activation. In vivo, we reproduced the structural and functional alterations in offspring of obese dams via the SMC-specific ablation of FoxO1. The reconstitution of FoxO1 using IL-6-deficient mice and pharmacological treatment did not protect against metabolic disorder but prevented SMC hyperproliferation. In human observational studies, childhood obesity was associated with reduced forced expiratory volume in 1s/forced vital capacity ratio Z-score (used as proxy for lung function) and asthma. We conclude that the interleukin-6-FoxO1 pathway in SMC is a molecular mechanism by which perinatal obesity programs the bronchial and vascular structures and functions, thereby driving CLD development. Thus, FoxO1 reconstitution provides a potential therapeutic option for preventing this metabolic programming of CLD.</p>

opencc-zeroApr 2022View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record